Last reviewed · How we verify
Placebo Eyedrops
Placebo eyedrops contain no active pharmaceutical ingredient and produce therapeutic effects through the placebo effect.
Placebo eyedrops contain no active pharmaceutical ingredient and produce therapeutic effects through the placebo effect. Used for Control comparator in ophthalmic clinical trials (specific indication depends on concurrent active treatment arm).
At a glance
| Generic name | Placebo Eyedrops |
|---|---|
| Also known as | Saline/ Benzalkonium Chloride (BAK) Ophthalmic Solution |
| Sponsor | Jaeb Center for Health Research |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Placebo eyedrops are used as a control comparator in clinical trials to assess the efficacy of active ophthalmic treatments by isolating the pharmacological effect from psychological and contextual factors. They may produce measurable clinical improvements through patient expectation and the natural history of the underlying condition. This formulation is typically used in Phase 3 trials to establish that an investigational drug performs better than placebo alone.
Approved indications
- Control comparator in ophthalmic clinical trials (specific indication depends on concurrent active treatment arm)
Common side effects
- Minimal adverse events expected (non-active formulation)
Key clinical trials
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- Lacripep for Corneal Wound Healing Study (PHASE2)
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye (PHASE4)
- A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) (PHASE3)
- Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) (PHASE2)
- Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease (NA)
- Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |